Chronic hepatitis C treatment in HIV co-infection in Portugal: Results from a cohort OF 2133 patients presented by GEPCOI (Portuguese Coinfection Study Group) by Miranda, AC et al.
J Viral Hepat. 2020;27:715–720.    |  715wileyonlinelibrary.com/journal/jvh
 
Received: 12 September 2019  |  Revised: 25 January 2020  |  Accepted: 6 February 2020
DOI: 10.1111/jvh.13281  
O R I G I N A L  P A P E R
Chronic hepatitis C treatment in HIV co-infection in Portugal: 
Results from a cohort OF 2133 patients presented by GEPCOI 
(Portuguese Coinfection Study Group)
Ana Cláudia Miranda1  |   Josefina Mendez2 |   Rosário Serrão3 |   Francisco Vale4 |    
Maria José Manata5 |   Sara Pinto6 |   André Gomes7 |   Cristina Valente8 |   
Patrícia Pacheco9 |   Rosário Pazos10 |   Rui Pereira11 |   Ana Martins12 |   
Isabel Germano13 |   Sónia Rocha14 |   Ana Paula Reis15 |   Rui Sarmento-Castro2
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2020 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
Number of patient included by hospital centre: Hospital de Egas Moniz: n = 332; Centro Hospitalar do Porto: n = 406; Centro Hospitalar de São João: n = 337; Centro Hospitalar de 
Setúbal: n = 211; Hospital de Curry Cabral: n = 185; Centro Hospitalar de Gaia/Espinho: n = 127; Hospital Garcia de Orta, EPE: n = 105;Centro Hospitalar e Universitário de Coimbra: 
n = 97; Hospital Fernando da Fonseca: n = 93; Hospital de Portimão: n = 89; Hospital de Faro: n = 47; Centro Hospitalar do Baixo Vouga: n = 39; Hospital de São José: n = 35; Unidade 
Local Saúde Alto Minho: n = 20; Hospital dos Marmeleiros: n = 10. 
GEPCOI members on behalf of participating centers: Kamal Mansinho, António Sarmento, José Poças, Fernando Maltez, Margarida Mota, Nuno Marques, Margarida Prata, José Saraiva 
da Cunha, Domitília Faria, Jorge Velez, Célia Oliveira, António Ferreira, Augusta Silva, Nancy Faria. 
Abbreviations: DAAs, direct-acting antiviral drugs; FS, fibroscan score; GEPCOI, Portuguese Study Group of Hepatitis and HIV Co-infection; HCV, Hepatitis C virus; HIV, human 
immunodeficiency virus; LDV, ledipasvir; ORs, Odds ratios; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virologic response.
1Serviço de Infecciologia e Medicina 
Tropical, Centro Hospitalar de Lisboa 
Ocidental, Hospital de Egas Moniz, Lisboa, 
Portugal
2Serviço de Doenças Infecciosas, Centro 
Hospitalar do Porto, Porto, Portugal
3Serviço de Doenças Infecciosas, Centro 
Hospitalar de São João, Porto, Portugal
4Serviço de Doenças Infecciosas, Centro 
Hospitalar de Setúbal, Setúbal, Portugal
5Serviço de Doenças Infecciosas, Centro 
Hospitalar Universitário de Lisboa Central, 
Hospital de Curry Cabral, Lisboa, Portugal
6Serviço de Doenças Infecciosas, Centro 
Hospitalar de Gaia/Espinho, Gaia/Espinho, 
Portugal
7Serviço de Infecciologia, Hospital Garcia de 
Orta, EPE, Almada, Portugal
8Serviço de Doenças Infecciosas, Centro 
Hospitalar e Universitário de Coimbra, 
Coimbra, Portugal
9Serviço de Doenças Infecciosas, Hospital 
Fernando da Fonseca, Amadora, Portugal
10Serviço de Medicina, Centro Hospitalar 
Universitário do Algarve, Hospital de 
Portimão, Portimão, Portugal
11Serviço de Doenças Infecciosas, Centro 
Hospitalar Universitário do Algarve, Hospital 
Abstract
Direct-acting antiviral drugs (DAAs) have recently changed the paradigm of hepatitis 
C therapy, significantly improving treatment response rates, patient life expectancy 
and quality of life. In Portugal, sofosbuvir (SOF) and SOF/ledipasvir (SOF/LDV) were 
fully reimbursed by the National Health System since early 2015 and generalized use 
of interferon-free DAA based regimens became current practice. During 2016, the re-
maining DAAs were sequentially added and covered by the same health access policy. 
The Portuguese Study Group of Hepatitis and HIV Co-infection (GEPCOI) collected 
data from 15 clinical centres in Portugal, pertaining to the HCV treatment experience 
with DAA regimens. A cohort of 2133 patients was analysed, representing one of the 
largest DAA treated HCV/HIV co-infected individuals. The global sustained virologic 
response (SVR) achieved was 95% in this real-life cohort setting. Linear regression 
analysis showed significant differences in treatment response rates when using SOF 
plus ribavirin (RBV) combination in genotype 2 or 3 infected individuals (P < .002) and 
in those with liver cirrhosis (P < .002). These findings corroborate that early treatment 
is mandatory in HIV/HCV co-infected patients, as response rates may be negatively 
influenced by higher fibrosis stages and suboptimal DAA regimens. The current na-
tional Portuguese health policy should continue to promote wider treatment access 
and individualized therapy strategies, aiming at the elimination of HCV infection in 
this high-risk co-infected population.
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1  | INTRODUC TION
Direct-acting antiviral drugs (DAAs) have recently changed the 
paradigm of chronic hepatitis C therapy, significantly improving 
treatment response rates, patient life expectancy and quality of 
life. Global prevalence estimates show that about 71 million peo-
ple are infected with HCV representing about 1% of the world's 
population, with an annual incidence of 1.75 million new infec-
tions. Worldwide, approximately 6.2% of human immunode-
ficiency virus (HIV) infected people are also co-infected with 
hepatitis C virus (HCV) (2.28 million), which translates to 2.4% of 
people living with HIV.
HCV affects over 80% of all intravenous drug users (PWID) and 
6.4% of men who have sex with other men (MSM).1 Of the approx-
imately 10.2 million people with chronic HCV in Europe, most are 
living in Eastern Europe (6.7 million) followed by Western Europe 
(2.3 million) and Central Europe (1.2 million), with an estimated 
HCV European prevalence of 1.5%.4-6 Unsafe health care practices 
and injection drug use perpetuates HCV transmission, in paral-
lel with increasing HCV-related liver disease burden, as a result of 
an ageing population infected during peak HCV epidemics in past 
decades. HCV-related disease represented the 7th global cause of 
death in 2015 (WHO data), and one of the main reasons for liver 
transplantation.
In 2016, the World Health Organization defined targets to elim-
inate HCV infection as a major public health threat by 2030, aiming 
at 80% reduction in new infections, 65% reduction in mortality and 
at least 80% of patients engaged in treatment. Portugal has been 
identified as one European country with a friendly advocate policy. 
Since early 2015, SOF and SOF/LDV were the first fully government 
reimbursed second-generation DAAs and generalized use of inter-
feron-free regimens became current practice. After July 2016, the 
remaining approved DAAs were sequentially added and covered by 
the same health access policy.
By the end of 2018, according to the national HCV treatment 
database registry (INFARMED) 20 337 HCV infected patients had 
started DAA treatment. The global SVR achieved until then was 
96.6% among 11 718 patients who had completed treatment and 
follow-up evaluation.7
The HCV/HIV co-infected population represents 22.4% 
(n = 4.957) of those proposed for DAA treatment in Portugal. 85% 
of these had already initiated HCV therapy. The SVR rate recorded 
among HCV/HIV co-infected patients was 95.9% (2.649 patients 
completed treatment and underwent SVR evaluation).10 HCV and 
HIV co-infected patients are still considered a priority to engage in 
HCV treatment due to faster liver disease progression. This paper 
aimed to describe a cohort of 2133 HCV/HIV co-infected patients 
that engaged in HCV treatment with DAA-containing regimens, from 
early 2015 until July 2018, reflecting a real-life clinical experience.
2  | PATIENTS AND METHODS
The Portuguese Study Group of Hepatitis and HIV Co-infection 
(GEPCOI) collected data from 15 hospital centres in Portugal, aim-
ing to better characterize the HCV treatment experience with DAA 
regimens in HCV/HIV co-infected populations. A common database 
was created allowing the participation of hospital centres to input 
the desired data. Inclusion criteria were adult HCV/HIV co-infected 
individuals who started therapy with a DAA interferon-free regimen, 
during the period between January 2015 and July 2018. Exclusion 
criteria were consistent with those defined by national and the 
European Association for the study of Liver Disease (EASL) guide-
lines, who do not recommend treatment in patients with limited life 
expectancy due to non–liver-related comorbidities, including he-
patic carcinoma in palliative care.2,3
A multicenter, retrospective, observational study of a real-life 
clinical cohort was conducted and included 2133 HCV chronically 
infected patients, with HIV co-infection. The study population was 
medically followed up at 15 different clinical centres across the 
country (Table 1). Demographic (age, gender and geographic or-
igin), epidemiological (HCV likely route of transmission and date 
of diagnosis), clinical (hepatic disease stage, presence of cirrho-
sis), immunological and virological (CD4+ lymphocytes count, HCV 
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genotype, HCV plasma RNA quantification and HIV plasma RNA 
quantification) and treatment (previous response to HCV treat-
ment, DAA regimen, duration and response after treatment) data 
were collected. Hepatic disease stage was accessed by clinical, 
laboratory and hepatic ultrasound evaluation, associated with 
noninvasive methods, such as hepatic elastography and/or APRI 
and FIB-4 serum biomarkers, which allowed categorization if cir-
rhosis was present. Patients with decompensated cirrhosis were 
not included in this analysis.
Data were collected from individual clinical files. The epidemi-
ological and clinical characteristics of patients treated for chronic 
hepatitis C with DAAs were evaluated and related to SVR. SVR was 
defined as HCV RNA undetectable at week 12 or 24 after treatment. 
When HCV RNA was not available (eg, lost to follow-up, death), 
patients were considered as not achieving SVR12. For categorical 
variables, we used the chi-square test and for continuous variables 
Student's t test for independent samples.
Liver cirrhosis was considered when patients had a fibroscan 
score (FS) above 12.5 KPa or when having an APRI score above 1.0 
and a FIB-4 score above 3.25.11,12 Multivariate logistic regression 
was used to determine whether there were any correlations between 
SVR and those independent variables with significant differences 
(P < .05) and of clinical interest. The predictive variables included 
were defined a priori and included gender, age, HCV genotype, pre-
vious HCV treatment, presence of cirrhosis, HCV RNA and DAA reg-
imen used (SOF/RBV vs others). Odds ratios (ORs) and P-values are 
presented where applicable. The significance level established for all 
analyses was .05. Data were analysed using the statistical software 
SPSS statistics, version 15.
3  | RESULTS
A total of 2133 patients were included in this study. Demographic 
characterization revealed a male predominance of 83% (n = 1769) 
and an average age of 46 years old (21-79). As expected, the vast 
majority (96%) were born in Portugal. The second most common ge-
ographic origin was represented by 49 African patients (2.3%), from 
Guinea Bissau, Angola, Mozambique, Cape Verde and São Tomé and 
Principe. Intravenous illicit drug use was the most frequent transmis-
sion route for HCV acquisition and was present in 91% (n = 1840) of 
patients, while sexual transmission was assumed in 8% (n = 171) of 
cases.
Considering previous exposure to HCV treatment, 69% (n = 1458) 
were naïve and the remaining 31% (n = 666) were past nonrespond-
ers mostly to dual therapy, based on pegylated interferon alpha plus 
RBV (PegIFN + RBV). Only nine patients (0.4%) had been previously 
exposed, without virologic response, to pegylated interferon alpha 
plus RBV plus a first generation protease inhibitor, namely telaprevir 
(TPV), boceprevir (BOC) or simeprevir (SMV).
Genotype prevalence found in this population was as follows: G1 
67.7% (n = 1445); G2 1.2% (n = 25); G3 15.3% (n = 326); G4 15.7% 
(n = 334); and G5/G6 0.1% (n = 3).
The stage of hepatic disease was assessed by clinical, laboratory 
and ultrasound evaluation. Additionally, noninvasive methods such 
as elastography were performed in most patients (n = 1972, 92.5%). 
One hundred and sixty-one patients (7.5%) did not have hepatic elas-
tography. Therefore, seromarkers for APRI and FIB4 scores were de-
termined, considering as cutoff values, 1.0 and 3.25, respectively. 
The joint evaluation of elastography and seromarkers made it pos-
sible to identify 1697 (79.6%) patients without cirrhosis and 20.4% 
(n = 436) with compensated cirrhosis (Table 2).
Immunological evaluation at baseline, before DAA treatment 
initiation, revealed a mean lymphocyte CD4+ count of 619 cel/mm3 
TA B L E  1   Geographic distribution of participating hospital 
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and 96% of patients on antiretroviral therapy were virologically sup-
pressed. Besides genotype and clinical evaluation, the prescription 
of DAA regimens was dictated by national and European therapeu-
tic guidelines and reimbursement national policies. During the study 
period, the most frequently prescribed regimens are listed in Table 3.
According to therapeutic guidelines at the time of treatment 
initiation, almost two thirds of patients were eligible for 12-week 
duration regimens (64%, n = 1365), and 34.7% (n = 740) had crite-
ria for 24 weeks of treatment, mostly regarding those infected by 
genotype 3. Only 19 patients (0.9%) were considered eligible for 
8 weeks treatment duration, mostly due to local hospital restriction 
guidelines at the time. Ribavirin was added in 21.6% (n = 461) of 
treatment regimens, highlighting the fact that 204 of those patients 
were infected by genotype 2 or 3 and initially began treatment with 
SOF plus RBV dual therapy, a regimen recommended by therapeutic 
guidelines at that time.
Overall SVR was 95%. The rate of therapeutic failure by relapse 
(n = 51) or virologic breakthrough (n = 3) was 2.5%. During the study 
period, 0.9% (n = 19) of patients died and 1.6% (n = 33) were lost to 
follow-up. SVR by HCV genotype was as follows: 96% for genotype 
1; 76% for genotype 2; 91% for genotype 3; and 96% for genotype 4 
(Figure 1). The SVR recorded according to the presence of cirrhosis 
was 95.4% in those without and 91.7% in those with compensated 
cirrhosis (P < .002). According to the different DAA regimens used, 
the corresponding SVR rate recorded is represented in Figure 2. 
Other baseline characteristics did not impact SVR, namely when 
gender (P = .183), patient age (P = .68) or HCV RNA level (P = .634) 
were evaluated. Linear regression analysis showed significant differ-
ences in treatment response rates when using SOF plus RBV combi-
nation (SOF/RBV) in genotype 2 or 3 infected individuals (P < .002) 
and in those with liver cirrhosis (P < .02).
4  | DISCUSSION
The WHO global HCV treatment cascade, published in 2015, doc-
umented a current gap of 78% in diagnosis, when considering the 
2030 set target of 90%, and a gap of 98% among those engaged 
in treatment, which translates into 1.76 million people treated until 
2015.8,9 Across Europe, it is estimated that only 36% of those living 
with chronic HCV infection have been diagnosed and only about 5% 
have been treated.4 A major barrier to enhancing HCV treatment 
uptake have been the restrictions established by stakeholders and 
decision-makers, including national governments and others, in re-
sponse to the initially unrealistic high cost of DAA therapies.
To our knowledge, this is one of the largest HCV/HIV co-infec-
tion cohorts ever published regarding treatment with DAAs in a re-
al-life setting. In an earlier stage, soon after sofosbuvir and other 
second-generation DAAs were approval, national treatment recom-
mendations privileged those patients with a more advanced stage 
of disease. Subsequent HCV national treatment recommendations 
updates rapidly extended the indication for everyone infected, cor-
relating with our findings, where 69% of our patients were naïve to 
HCV treatment and 20.4% had advanced liver disease and compen-
sated cirrhosis.3
According to the guidelines at that time, 84% of patients were 
eligible to start treatment with SOF/LDP regimens. The high SVR of 
TA B L E  2   Study population demographic and HCV baseline 
characterization
Male gender (%) 83
Mean age (y) 46 (21-79)
Portuguese origin (%) 96
Intravenous drug use transmission (%) 91
HCV treatment naïve (%) 69
Genotype 1 (%) 67.7
Genotype 3 (%) 15.3
Genotype 4 (%) 15.7
Cirrhosis (%) 20.4
Mean plasma baseline HCV RNA (IU/mL) 4.430.389





SOF + RBV 204 (9.6)
SOF + DCV 54 (2.5)
3D 43 (2)
SOF + PR 24 (1.1)
GZV/EBV 15 (0.7)
SOF/VEL 7 (0.3)
SOF + SMV 2 (0.1)
Note: SOF/LDV (sofosbuvir/ledipasvir).
SOF/RBV (sofosbuvir/ribavirin).
SOF + DCV (sofosbuvir plus daclatasvir).
3D (paritaprevir/ombitasvir + dasabuvir).
SOF + PR (sofosbuvir plus pegylated interferon alpha plus ribavirin).
GZR/EBR (grazoprevir/elbasvir).
SOF/VEL (sofosbuvir/velpatasvir).
SOF/SMV (sofosbuvir plus simeprevir).
F I G U R E  1   Sustained virologic response rates (%) by HCV 
genotype (N = 2133)
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96% registered in this group was concordant with the results pub-
lished in previous clinical trials.
The second most frequent regimen prescribed was SOF/RBV 
(10%), recommended at that time for genotype 2 or 3 infected pa-
tients, with a significantly lower SVR (87%), related to the use of a, 
nowadays admitted, less powerful and effective combination. RBV 
was added in 21.6% of DAA regimens prescribed and over a third of 
patients (34.7%) completed a period of 24 weeks of treatment. A small 
percentage of patients (0.9%) completed an 8 weeks short treatment. 
The lower SVR achieved with the SOF/VEL (86%) regimen should be 
cautiously interpreted related to the small number of patients so far 
included (Figure 2). Significantly lower SVR rates were evident in gen-
otype or 3 infected patients (76% and 91%, respectively) and in those 
with cirrhosis (91.7% vs 95.4% in the absence of cirrhosis).
This study has some limitations related to its retrospective de-
sign, as such, the lack of histological confirmation of hepatic cir-
rhosis, since although it remains the gold standard, liver biopsy has 
been replaced by noninvasive indirect methods. The extremely rapid 
evolution of HCV treatment guidelines, recently driven by the ap-
proval of pangenotypic DAA regimens, renders the use of some of 
these therapeutic combinations obsolete, not neglecting, however, 
the overall high SVR obtained (95%) in this cohort. Current national 
policy continues to promote the reimbursement of all approved 
DAAs, allowing for increased and convenient use of pangenotypic 
regimens.
The HCV/HIV co-infected population is an obvious target for 
micro elimination strategy implementation. Micro elimination could 
be defined as a plan that adapts and allocates available resources 
and health services, removes barriers and achieves high diagnostic 
levels and HCV treatment engagement, in this specific population of 
interest.8 These ambitious strategies should be ruled by mathemat-
ical modelling estimates, adapted to local epidemiology, in a tempo-
rary target setting and depends on a health policy definition, with 
active involvement of government representatives, technical health 
and civil society members.10
In conclusion, this real-life Portuguese experience shows a high 
overall SVR rate of 95%, in a large HCV/HIV co-infected clinical 
cohort. The rapid emergence of newer generation DAAs in recent 
years and the scientific evidence evolution renders the use of some 
treatment combinations described herein as obsolete.
After a short 3 years use of DAA therapy, a huge clinical experi-
ence has been acquired, strengthening the enthusiasm of witnessing 
the gain in quality of life of our patients. This HCV/HIV co-infected 
population is an obvious target for implementation of a micro elimi-
nation strategy that could be achieved if the current and, hopefully 
future trend, in reimbursement of Portuguese health policy will con-
tinue. Such a strategy will promote wider access and individualized 
treatment options, aiming at the elimination of HCV infection in this 
high-risk population of people living with HIV.
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